Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Bioanalysis ; 4(9): 1025-37, 2012 May.
Article in English | MEDLINE | ID: mdl-22612684

ABSTRACT

BACKGROUND: A frequent impediment to accurate quantitation in bioanalytical LC-MS arises from carryover. For many new chemical entities in drug discovery carryover is not limited to the autosampler, but instead arises from several different sources. METHOD: We tested several different columns, injector wash sequences and gradient compositions to understand and eliminate these sources. In many instances carryover was dictated by the elution gradient and column as much as the autosampler hardware and wash protocol. CONCLUSION: Several trends were observed. First, different columns resulted in significantly different amounts of carryover (even for nominally the same column chemistry). Second, a continuous high organic wash of the column was not as effective at removing carryover as cycling between high and low organic mobile phases during the column wash. Combining our observations (column, gradient and autosampler configuration) we devised a short 3-min method that is appropriate for a diverse set of new chemical entities and minimizes carryover while still being sufficiently robust to use in a drug-discovery setting.


Subject(s)
Chromatography, High Pressure Liquid/methods , Mass Spectrometry/methods , Pharmaceutical Preparations/analysis , Animals , Automation , Chemistry, Pharmaceutical/methods , Chemistry, Pharmaceutical/standards , Chromatography, High Pressure Liquid/standards , Mass Spectrometry/standards , Plasma/chemistry , Quality Control , Rats
2.
J Biol Chem ; 285(46): 35471-8, 2010 Nov 12.
Article in English | MEDLINE | ID: mdl-20826813

ABSTRACT

Endocannabinoids are lipid signaling molecules that act via G-coupled receptors, CB(1) and CB(2). The endocannabinoid system is capable of activation of distinct signaling pathways on demand in response to pathogenic events or stimuli, hereby enhancing cell survival and promoting tissue repair. However, the role of endocannabinoids in hematopoietic stem and progenitor cells (HSPCs) and their interaction with hematopoietic stem cells (HSC) niches is not known. HSPCs are maintained in the quiescent state in bone marrow (BM) niches by intrinsic and extrinsic signaling. We report that HSPCs express the CB(1) receptors and that BM stromal cells secrete endocannabinoids, anandamide (AEA) (35 pg/10(7) cells), and 2-AG (75.2 ng/10(7) cells). In response to the endotoxin lipopolysaccharide (LPS), elevated levels of AEA (75.6 pg/10(7) cells) and 2-AG (98.8 ng/10(7) cells) were secreted from BM stromal cells, resulting in migration and trafficking of HSPCs from the BM niches to the peripheral blood. Furthermore, administration of exogenous cannabinoid CB(1) agonists in vivo induced chemotaxis, migration, and mobilization of human and murine HSPCs. Cannabinoid receptor knock-out mice Cnr1(-/-) showed a decrease in side population (SP) cells, whereas fatty acid amide hydrolase (FAAH)(-/-) mice, which have elevated levels of AEA, yielded increased colony formation as compared with WT mice. In addition, G-CSF-induced mobilization in vivo was modulated by endocannabinoids and was inhibited by specific cannabinoid antagonists as well as impaired in cannabinoid receptor knock-out mice Cnr1(-/-), as compared with WT mice. Thus, we propose a novel function of the endocannabinoid system, as a regulator of HSPC interactions with their BM niches, where endocannabinoids are expressed in HSC niches and under stress conditions, endocannabinoid expression levels are enhanced to induce HSPC migration for proper hematopoiesis.


Subject(s)
Bone Marrow Cells/metabolism , Cannabinoid Receptor Modulators/biosynthesis , Endocannabinoids , Hematopoietic Stem Cells/metabolism , Stromal Cells/metabolism , Amidohydrolases/genetics , Amidohydrolases/metabolism , Animals , Arachidonic Acids/biosynthesis , Blotting, Western , Bone Marrow Cells/cytology , Cannabinoid Receptor Modulators/physiology , Cell Communication/physiology , Cell Movement/drug effects , Cells, Cultured , Cyclohexanols/pharmacology , Female , Flow Cytometry , Glycerides/biosynthesis , Hematopoietic Stem Cell Mobilization , Hematopoietic Stem Cells/cytology , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Polyunsaturated Alkamides , Receptor, Cannabinoid, CB1/agonists , Receptor, Cannabinoid, CB1/genetics , Receptor, Cannabinoid, CB1/metabolism , Receptor, Cannabinoid, CB2/agonists , Receptor, Cannabinoid, CB2/genetics , Receptor, Cannabinoid, CB2/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Side-Population Cells/cytology , Side-Population Cells/metabolism , Stem Cell Niche/cytology , Stem Cell Niche/metabolism , Stromal Cells/cytology
3.
J Lipid Res ; 51(6): 1416-23, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20071693

ABSTRACT

The endocannabinoid metabolome consists of a growing, (patho)physiologically important family of fatty-acid derived signaling lipids. Diet is a major source of fatty acid substrate for mammalian endocannabinoid biosynthesis. The principal long-chain PUFA found in mammalian brain, docosahexaenoic acid (DHA), supports neurological function, retinal development, and overall health. The extent to which dietary DHA supplementation influences endocannabinoid-related metabolites in brain, within the context of the circulating endocannabinoid profile, is currently unknown. We report the first lipidomic analysis of acute 2-week DHA dietary supplementation effects on the physiological state of 15 fatty-acid, N-acylethanolamine, and glycerol-ester endocannabinoid metabolome constituents in murine plasma and brain. The DHA-rich diet markedly elevated DHA, eicosapentaenoic acid, 2-eicosapentanoylglycerol (EPG), and docosahexanoylethanolamine in both compartments. Dietary DHA enhancement generally affected the synthesis of the N-acyl-ethanolamine and glycerol-ester metabolites to favor the docosahexaenoic and eicosapentaenoic vs. arachidonoyl and oleoyl homologs in both brain and plasma. The greater overall responsiveness of the endocannabinoid metabolome in plasma versus brain may reflect a more circumscribed homeostatic response range of brain lipids to dietary DHA supplementation. The ability of short-term DHA enhancement to modulate select constituents of the physiological brain and plasma endocannabinoid metabolomes carries metabolic and therapeutic implications.


Subject(s)
Brain/drug effects , Brain/metabolism , Cannabinoid Receptor Modulators/blood , Cannabinoid Receptor Modulators/metabolism , Dietary Supplements , Docosahexaenoic Acids/pharmacology , Endocannabinoids , Animals , Body Weight/drug effects , Chromatography, Liquid , Ethanolamines/metabolism , Fatty Acids, Unsaturated/metabolism , Glycerol/chemistry , Glycerol/metabolism , Lipid Metabolism/drug effects , Male , Metabolome/drug effects , Mice , Tandem Mass Spectrometry , Time Factors
4.
Clin Chem Lab Med ; 46(9): 1289-95, 2008.
Article in English | MEDLINE | ID: mdl-18611105

ABSTRACT

BACKGROUND: Endogenous cannabinoid-receptor ligands (endocannabinoids) and over a dozen related metabolites now comprise the "endocannabinoid metabolome". The diverse (patho)physiological roles of endocannabinoids, the predictive/diagnostic utility of systemic endocannabinoid levels, and the growing interest in endocannabinoid-related pharmacotherapeutics mandate a valid clinical protocol for processing human blood that does not jeopardize profiling of the circulating endocannabinoid metabolome. METHODS: We systematically evaluated the potential effect of pre-analytical variables associated with phlebotomy and sample handling/work-up on the human-blood endocannabinoid metabolome as quantified by state-of-the-art liquid chromatography-mass spectrometry. RESULTS: Neither subject posture during phlebotomy nor moderate activity beforehand influenced the blood levels of the 15 endocannabinoid-system lipids quantified. Storage of fresh blood at 4 degrees C selectively enhanced ethanolamide concentrations artifactually without affecting monoglycerides and nonesterified fatty acids, such as arachidonic acid. In marked contrast, ethanolamides and monoglycerides remained stable through three plasma freeze/thaw cycles, whereas plasma arachidonic acid content increased, probably a reflection of ongoing metabolism. CONCLUSIONS: Class- and compound-selective pre-analytical influences on circulating human endocannabinoid levels necessitate immediate plasma preparation from fresh blood and prompt plasma apportioning and snap-freezing. Repeated plasma thawing and refreezing should be avoided. This protocol ensures sample integrity for evaluating the circulating endocannabinoid metabolome in the clinical setting.


Subject(s)
Blood Circulation , Blood Specimen Collection/methods , Cannabinoid Receptor Modulators/blood , Cannabinoid Receptor Modulators/metabolism , Endocannabinoids , Adolescent , Adult , Animals , Cannabinoid Receptor Modulators/isolation & purification , Cattle , Female , Humans , Motor Activity , Posture , Reference Values , Sensitivity and Specificity , Temperature
5.
J Pharmacol Exp Ther ; 322(3): 1059-66, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17545313

ABSTRACT

Endocannabinoids are released in response to pathogenic insults, and inhibitors of endocannabinoid inactivation enhance such on-demand responses that promote cellular protection. Here, AM374 (palmitylsulfonyl fluoride), an irreversible inhibitor of fatty acid amide hydrolase (FAAH), was injected i.p. into rats to test for endocannabinoid enhancement. AM374 caused a prolonged elevation of anandamide levels in several brain regions, including the hippocampus, and resulted in rapid activation of the extracellular signal regulated-kinase/mitogen-activated protein kinase pathway that has been linked to survival. To evaluate the neuroprotective nature of the FAAH inhibitor, we tested AM374 in a seizure model involving rats insulted with kainic acid (KA). AM374 was injected immediately after KA administration, and seizure scores were significantly reduced throughout a 4-h observation period. The KA-induced seizures were associated with calpain-mediated cytoskeletal breakdown, reductions in synaptic markers, and loss of CA1 hippocampal neurons. FAAH inhibition protected against the excitotoxic damage and neuronal loss assessed 48 h postinsult. AM374 also preserved pre- and postsynaptic markers to levels comparable with those found in noninsulted animals, and the synaptic marker preservation strongly correlated with reduced seizure scores. With regard to behavioral deficits in the excitotoxic rats, AM374 produced nearly complete functional protection, significantly improving balance and coordination across different behavioral paradigms. These data indicate that AM374 crosses the blood-brain barrier, enhances endocannabinoid responses in key neuronal circuitries, and protects the brain against excitotoxic damage.


Subject(s)
Cannabinoid Receptor Modulators/physiology , Endocannabinoids , Kainic Acid/adverse effects , Seizures/chemically induced , Amidohydrolases/antagonists & inhibitors , Animals , Arachidonic Acids/analysis , Brain/metabolism , Brain/pathology , Hippocampus/pathology , MAP Kinase Signaling System , Neuroprotective Agents/pharmacokinetics , Neuroprotective Agents/pharmacology , Palmitates/pharmacokinetics , Palmitates/pharmacology , Polyunsaturated Alkamides/analysis , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...